
AST SpaceMobile Secures Additional $100.0 Million of Liquidity from Non-Dilutive Equipment Financing
'This new non-dilutive financing enables AST SpaceMobile to continue its strong momentum executing against its accelerated operational plans,' said Andrew Johnson, Chief Financial Officer of AST SpaceMobile. 'This facility is the first such type of financing agreement for the company and reflects our stage of rapid growth and transition from Research & Development to full-scale manufacturing and network deployment.'
This non-dilutive financing provides an additional $100.0 million of long-term liquidity, including $25.0 million drawn at closing against previously purchased equipment, available through 2031. The facility uses existing and planned equipment as collateral and is designed to fit into a more mature, long-term capital structure, facilitating future debt capital, enabling flexibility and facilitating continued growth.
The company's capital structure continues to mature through a robust funding strategy, demonstrated by the successful convertible note issuance in January 2025, the retirement of approximately half the convertible notes after a share price increase of over 100% within six months, the diligent and prudent use of the 2025-issued At-the-Market facility, while concluding the second quarter with over $900.0 million in cash, cash equivalents, and restricted cash.
About AST SpaceMobile
AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on our extensive IP and patent portfolio, and designed for both commercial and government applications. Our engineers and space scientists are on a mission to eliminate the connectivity gaps faced by today's five billion mobile subscribers and finally bring broadband to the billions who remain unconnected. For more information, follow AST SpaceMobile on YouTube, X (formerly Twitter), LinkedIn and Facebook. Watch this video for an overview of the SpaceMobile mission.
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies. With five distinct business verticals–Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences–Trinity Capital stands as a long-term trusted partner for innovative companies seeking tailored debt solutions. Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and in London (UK). For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).
Forward-Looking Statements
This communication contains 'forward-looking statements' that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes,' 'estimates,' 'anticipates,' 'expects,' 'intends,' 'plans,' 'may,' 'will,' 'would,' 'potential,' 'projects,' 'predicts,' 'continue,' or 'should,' or, in each case, their negative or other variations or comparable terminology. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside AST SpaceMobile's control and are difficult to predict.
Factors that could cause such differences include, but are not limited to: (i) expectations regarding AST SpaceMobile's strategies and future financial performance, including AST's future business plans or objectives, expected functionality of the SpaceMobile Service, anticipated timing of the launch of the Block 2 BlueBird satellites, anticipated demand and acceptance of mobile satellite services, prospective performance and commercial opportunities and competitors, the timing of obtaining regulatory approvals, ability to finance its research and development activities, commercial partnership acquisition and retention, products and services, pricing, marketing plans, operating expenses, market trends, revenues, liquidity, cash flows and uses of cash, capital expenditures, and AST SpaceMobile's ability to invest in growth initiatives; (ii) the negotiation of definitive agreements with mobile network operators relating to the SpaceMobile Service that would supersede preliminary agreements and memoranda of understanding and the ability to enter into commercial agreements with other parties or government entities; (iii) the ability of AST SpaceMobile to grow and manage growth profitably and retain its key employees and AST SpaceMobile's responses to actions of its competitors and its ability to effectively compete; (iv) changes in applicable laws or regulations; (v) the possibility that AST SpaceMobile may be adversely affected by other economic, business, and/or competitive factors; (vi) the outcome of any legal proceedings that may be instituted against AST SpaceMobile; and (vii) other risks and uncertainties indicated in the Company's filings with the Securities and Exchange Commission (SEC), including those in the Risk Factors section of AST SpaceMobile's Form 10-K filed with the SEC on March 3, 2025 and Form 10-Q filed with the SEC on May 12, 2025.
AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile's Form 10-K filed with the SEC on March 3, 2025 and Form 10-Q filed with the SEC on May 12, 2025. AST SpaceMobile's securities filings can be accessed on the EDGAR section of the SEC's website at www.sec.gov. Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Intel Rallies Despite Fitch Downgrade
Intel (NASDAQ:INTC) got a surprise downgrade from Fitch this week, yet its stock popped about 3.6% anyway. The agency dialed down Intel's long-term credit rating from BBB+ to BBB, pointing to a tougher demand backdrop and the need for debt reduction and stronger product ramps over the next year or two. Short-term ratings stayed at F2, so it's not all doom and gloom. Warning! GuruFocus has detected 6 Warning Signs with INTC. At the same time, Intel's next-gen 18A process is acting up. Early reports suggest Panther Lake chips have roughly three times the defect rate they should, and volume ramps are lagging. That's a headache so close to the planned Q4 launch, especially when smooth ramp-up was supposed to prove we're past the worst of manufacturing woes. Still, investors seem to be looking past the short-term noise. Maybe a rebound in PC and data-center spendingor a clean bill of health at the August 12 bond covenant updatewill do the trick. The real verdict, though, will come with Q3 production progress and any signs that Panther Lake irons out its kinks. This article first appeared on GuruFocus.
Yahoo
26 minutes ago
- Yahoo
Recursion Sets $100 Million Partnership Goal by 202
Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher Gibson talked up how the Exscientia tech and the Boltz-2 partnership with MIT and Nvidia have supercharged their end-to-end platformfrom pinpointing targets to simulating trials. That boost in efficiency shines through in their finances. Warning! GuruFocus has detected 6 Warning Signs with RXRX. CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of 2026, which should carry them all the way through Q4 2027 without needing extra financing. On the science side, six internal programs are nearing key milestones. Oncology dose-escalation data should roll in by year-end and rare-disease updates are due early next year. The ClinTech AI platform now promises roughly 50 % faster enrollment projections, and they've hit a fourth Sanofi milestone while rolling out neuronal phenomaps with Roche and Genentech. This article first appeared on GuruFocus.


Business Upturn
30 minutes ago
- Business Upturn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Altimmune, Inc. ('Altimmune' or the 'Company') (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Dave Collier v. Altimmune, Inc., et al. (Case No. 8:25-cv-02581) has been commenced in the United States District Court for the District of Maryland. To get more information go to: Altimmune Lawsuit Submission Form or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you. According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune's common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day. If you suffered a loss in ALT securities, you have until October 6, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171